Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2015 / Sep / Aflibercept in Europe: Setting New Standards in Retinal Disease Care
Retina Retina

Aflibercept in Europe: Setting New Standards in Retinal Disease Care

Strength and durability in the real world

9/9/2015 1 min read

Share

Highlights from Bayer HealthCare’s Satellite Symposium ‘Aflibercept in Europe: Setting new standards in retinal disease care,’ held on June 7, 2015, at the European Society of Ophthalmology Congress, Vienna, Austria This supplement is a write-up of a promotional meeting organized and funded by Bayer HealthCare. The speakers were paid honoraria toward this meeting. Bayer HealthCare checked the content for factual accuracy, to ensure it is fair and balanced, and that it complies with the ABPI Code of Practice. The views and opinions of the speakers are not necessarily those of Bayer HealthCare or the publisher. No part of this publication may be reproduced in any form without the permission of the publisher.

Articles:

Real World Data in Wet AMD: The National Aflibercept Audit
James Talks, Medical Retina Service, Royal Victoria Infirmary, Newcastle upon Tyne, UK Practical Benefits in Treatment Management
Sebastian Wolf, Department of Ophthalmology, Bern University Hospital, Bern, Switzerland Treating Visual Impairment Due to DME and Macular Edema Secondary to BRVO with Aflibercept: The Highlights
Edoardo Midena, Professor of Ophthalmology and Visual Sciences at the University of Padova, School of Medicine, and Chairman of the Department of Ophthalmology, Padova University Hospital, Padova, Italy
Download the pdf here

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: